HomeCompareSPHRY vs YUM

SPHRY vs YUM: Dividend Comparison 2026

SPHRY yields 66.67% · YUM yields 1.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPHRY wins by $790.7K in total portfolio value
10 years
SPHRY
SPHRY
● Live price
66.67%
Share price
$3.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$898.6K
Annual income
$227,458.53
Full SPHRY calculator →
YUM
YUM
● Live price
1.86%
Share price
$154.59
Annual div
$2.88
5Y div CAGR
51.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.9K
Annual income
$40,443.52
Full YUM calculator →

Portfolio growth — SPHRY vs YUM

📍 SPHRY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPHRYYUM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPHRY + YUM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPHRY pays
YUM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPHRY
Annual income on $10K today (after 15% tax)
$5,666.67/yr
After 10yr DRIP, annual income (after tax)
$193,339.75/yr
YUM
Annual income on $10K today (after 15% tax)
$158.35/yr
After 10yr DRIP, annual income (after tax)
$34,376.99/yr
At 15% tax rate, SPHRY beats the other by $158,962.76/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPHRY + YUM for your $10,000?

SPHRY: 50%YUM: 50%
100% YUM50/50100% SPHRY
Portfolio after 10yr
$503.3K
Annual income
$133,951.03/yr
Blended yield
26.62%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YUM right now

SPHRY
No analyst data
Altman Z
9.3
Piotroski
3/9
YUM
Analyst Ratings
18
Buy
30
Hold
3
Sell
Consensus: Hold
Price Target
$173.15
+12.0% upside vs current
Range: $158.00 — $190.00
Altman Z
2.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPHRY buys
0
YUM buys
0
No recent congressional trades found for SPHRY or YUM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPHRYYUM
Forward yield66.67%1.86%
Annual dividend / share$2.00$2.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.4%
Portfolio after 10y$898.6K$107.9K
Annual income after 10y$227,458.53$40,443.52
Total dividends collected$759.4K$81.2K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: SPHRY vs YUM ($10,000, DRIP)

YearSPHRY PortfolioSPHRY Income/yrYUM PortfolioYUM Income/yrGap
1← crossover$17,367$6,666.67$10,982$282.06+$6.4KSPHRY
2$29,403$10,820.35$12,189$438.29+$17.2KSPHRY
3$48,582$17,120.96$13,731$688.32+$34.9KSPHRY
4$78,421$26,438.17$15,789$1,097.12+$62.6KSPHRY
5$123,795$39,884.53$18,679$1,785.08+$105.1KSPHRY
6$191,303$58,842.62$22,975$2,988.18+$168.3KSPHRY
7$289,676$84,982.16$29,784$5,200.49+$259.9KSPHRY
8$430,218$120,263.91$41,408$9,539.16+$388.8KSPHRY
9$627,260$166,927.04$63,071$18,765.27+$564.2KSPHRY
10$898,627$227,458.53$107,930$40,443.52+$790.7KSPHRY

SPHRY vs YUM: Complete Analysis 2026

SPHRYStock

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Full SPHRY Calculator →

YUMConsumer Discretionary

YUM! Brands, Inc., together with its subsidiaries, develops, operates, and franchises quick service restaurants worldwide. It operates through four segments: the KFC Division, the Taco Bell Division, the Pizza Hut Division, and the Habit Burger Grill Division. The company operates restaurants under the KFC, Pizza Hut, Taco Bell, and The Habit Burger Grill brands, which specialize in chicken, pizza, made-to-order chargrilled burgers, sandwiches, Mexican-style food categories, and other food products. As of December 31, 2021, it had 26,934 KFC units; 18,381 Pizza Hut units; 7,791 Taco Bell units; and 318 The Habit Burger Grill units in approximately 157 countries and territories. The company was formerly known as TRICON Global Restaurants, Inc. and changed its name to YUM! Brands, Inc. in May 2002. YUM! Brands, Inc. was incorporated in 1997 and is headquartered in Louisville, Kentucky.

Full YUM Calculator →
📬

Get this SPHRY vs YUM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPHRY vs SCHDSPHRY vs JEPISPHRY vs OSPHRY vs KOSPHRY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.